Waystar Trading Volume Spikes as CPPIB and Bain Capital Boost Stakes Ahead of True North Conference
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Waystar HLDG Corp (NASDAQ: WAY) operates a revenue cycle management platform that integrates artificial intelligence to streamline healthcare payments and administrative processes. As of August 28, 2025, the stock closed at $37.17, unchanged from the previous session, on an exchange volume of 122,949 shares—a significant increase compared to its recent average volume. The company provides services that include financial clearance, patient financial care, revenue capture, claims and payer payment management, denial prevention and recovery, as well as analytics and reporting.
Corporate Structure
Waystar employs between 1,001 and 5,000 professionals who specialize in software development, client services, and healthcare finance. The board of directors and leadership team comprise individuals from various sectors including healthcare, finance, and technology. Notable members include Matt Hawkins as Chief Executive Officer and John Driscoll as Independent Board Chairman, with additional representation from EQT, Bain Capital, Canada Pension Plan Investment Board, JPMorgan International, Guidewire, UPMC, and Google Cloud.
Revenue Cycle by Bit Cloud
Recent Developments
On August 12, 2025, Waystar filed a Form 8-K (items 1.01, 2.03, and 7.01) with the SEC. Two Schedule 13G/A amendments dated August 14, 2025, disclosed significant institutional stakes: the Canada Pension Plan Investment Board reported ownership of 14.3% (24,964,225 shares as of July 21, 2025), while entities related to Bain Capital held 10.4% (18,055,049 shares as of June 30, 2025). The company is scheduled to host its True North conference from September 15–17, 2025, at the Gaylord Opryland Resort & Convention Center in Nashville, Tennessee.
Financial and Strategic Analysis
Waystar’s market capitalization was approximately $6.48 billion on August 28, 2025. The following table summarizes key metrics (trailing twelve months, unless noted):
| Metric | Value |
|---|---|
| Enterprise Value | $7.39 B |
| Price/Earnings (TTM) | 67.58 |
| Forward P/E | 26.95 |
| Price/Sales (TTM) | 6.49 |
| Price/Book (MRQ) | 2.04 |
| Enterprise Value/Revenue | 7.31 |
| Enterprise Value/EBITDA | 19.69 |
| Profit Margin | 8.50% |
| Return on Assets | 3.09% |
| Return on Equity | 2.81% |
| Revenue | $1.01 B |
| Net Income | $85.94 M |
| Total Cash (MRQ) | $341.58 M |
| Total Debt/Equity (MRQ) | 39.60% |
| Levered Free Cash Flow | $299.25 M |
The company’s platform leverages generative AI and automation to verify insurance benefits, automate prior authorizations, optimize claims processing, appeal denials, and deliver analytics in real time. Waystar AltitudeAI™ is integrated across various modules to enhance task prioritization and reduce errors.
Market Position and Industry Context
Waystar serves more than 30,000 clients—including 16 of the top 20 U.S. hospitals—processing over 5 billion transactions annually and providing services to approximately 50% of the U.S. patient population. Independent surveys from September 2023 indicated a provider net promoter score of 74 or higher. The company holds certifications such as HITRUST CSF, SOC 2, PCI DSS compliance, and has received rankings from Black Book and recognitions from Forbes and the International Business Awards.
In the revenue cycle management market, Waystar competes with both traditional healthcare software vendors and emerging insurtech firms. The company differentiates itself through its end-to-end AI capabilities and integrated analytics.
TL;DR
On August 12, 2025, Waystar filed an 8-K detailing key corporate events. Two Schedule 13G/A amendments on August 14 revealed a 14.3% ownership stake by the Canada Pension Plan Investment Board and a 10.4% stake by Bain Capital entities. Shares traded at $37.17 on August 28, accompanied by a notable increase in trading volume. The company’s True North conference is scheduled for September 15–17, 2025, with its next earnings release following the report on July 30, 2025. Analysts’ one-year target is set at $50.38.